Table 5. Univariate analysis of disease-free survival.
Variable | p-value* |
---|---|
Entire group | |
T stage (1 vs. 2–3) | 0.054 |
N stage (0 vs. 1–3) | 0.009 |
Histologic grade (I–II vs. III) | 0.357 |
Lymphovascular invasion (absent vs. present) | 0.043 |
p53 overexpression (absent vs. present) | 0.517 |
Ki-67 index ( < 20% vs. ≥ 20%) | 0.202 |
Hormone receptor (negative vs. positive) | 0.944 |
HER2 (negative vs. positive) | 0.394 |
Subtype (LA vs. LB vs. HER2+ vs. TN) | 0.549 |
Adjuvant chemotherapy (not received vs. received) | 0.526 |
Adjuvant radiotherapy (not received vs. received) | 0.242 |
Adjuvant hormone therapy (not received vs. received) | 0.843 |
miR-222 expression level (low vs. high) | 0.117 |
Hormone receptor-positive subgroup | |
T stage (1 vs. 2–3) | 0.037 |
N stage (0 vs. 1–3) | 0.138 |
Histologic grade (I–II vs. III) | 0.357 |
Lymphovascular invasion (absent vs. present) | 0.213 |
p53 overexpression (absent vs. present) | 0.168 |
Ki-67 index ( < 20% vs. ≥ 20%) | 0.159 |
HER2 (negative vs. positive) | 0.467 |
Subtype (LA vs. LB) | 0.173 |
Adjuvant chemotherapy (not received vs. received) | 0.632 |
Adjuvant radiotherapy (not received vs. received) | 0.320 |
miR-222 expression level (low vs. high) | 0.021 |
HER2=human epidermal growth factor receptor 2; LA=luminal A; LB=luminal B; TN=triple-negative; miR-222=microRNA-222.
*p-values were calculated by the log-rank test.